The weight figure in this review is the one that gets quoted, and it is the one every expectation is built from. The number that decides whether a twelve-month commitment is a good idea is the other one.
What was pooled
Four randomized trials of injected semaglutide in adults with overweight or obesity and without type 2 diabetes, 3,613 participants, searched across four databases to March 2025. [1] That population matters: it is the one most sellers on this roster actually serve.
Weight fell 11.85 percentage points more than placebo, 95% CI −12.81 to −10.90. Gastro intestinal adverse events were significantly more frequent, led by nausea, vomiting, diarrhea and constipation. Serious adverse events, including acute pancreatitis and gallstones, were uncommon.
The number that prices a commitment
Discontinuation because of adverse events occurred about 2.62 times as often on semaglutide as on placebo, 95% CI 1.70 to 4.03.
Why that is a money question
Because the cheapest advertised rates in this market require committing in advance. A buyer signing a multi-month term is betting that they will not be in the group that stops for side effects, and this review says that group is meaningfully larger on the drug than off it.
Nobody can tell in advance which group they are in. Early tolerability does not predict much either — in a large post hoc analysis, gastrointestinal events looked similar whether or not somebody was responding quickly. So the commitment is made before the relevant information exists, which is what the term checker is for.
The reassuring half
Serious adverse events were uncommon, and that includes the two most feared ones — pancreatitis and gallstones. The events driving discontinuation are unpleasant rather than dangerous: nausea, vomiting, diarrhea, constipation.
That distinction is worth holding. A drug people stop because it makes them feel sick is a different problem from a drug people stop because it hurts them, and only the first is addressable with dose and pace. It is also why what sellers charge for a gentler experience is worth scrutinizing rather than dismissing.
What to do with it
Read the weight figure and the discontinuation figure as one package. An 11.85-point advantage over placebo is large and real, and it is the advantage available to people who keep taking it. Persistence in this market is poor for several reasons at once, and side effects are one of them.
The authors ask for longer trials on durability and long-term safety, which is the standing gap in this entire literature. Four trials is not many for a drug this widely taken.